OGI Stock Analysis: Buy, Sell, or Hold?
OGI - Organigram Global Inc. Common Shares
$1.40
-0.04 (-2.78%)
▼
5d:
-2.78%
30d:
+6.87%
90d:
-15.15%
BUY
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 11, 2026
11d
Smart Money Accumulation
OGI is down 5.6% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 4,266 OI. Call ratio: 100% View Scanner →
Strength: 7.8/10
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: OGI shows positive signals but monitor for confirmation. Market pricing in 4.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: OGI shows positive signals but monitor for confirmation. Market pricing in 4.9% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $1.40, which is considered fair relative to its 30-day fair value range of $1.33 to $1.48. From a valuation perspective, the stock is trading at a discount (Forward PE: 58.3) compared to its historical average (67.9). Remarkably, the market is currently pricing in an annual earnings decline of 4.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.80 (+528.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OGI is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.80 (+528.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.33 -
$1.48
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 528.6% below Wall St target ($8.80)
Trading Range Analysis
30-Day Trading Range
$1.33 -
$1.48
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$1.67
Current Trend
Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
58.33
Wall Street Target
$8.80
(+528.6%)
Revenue Growth (YoY)
48.7%
Profit Margin
6.5%
Valuation Discount vs History
-4.9% cheaper
PE vs Historical
58.3 vs 67.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.9%
(market-implied from PE analysis)
1-Year Target
$1.33
(-5%)
2-Year Target
$1.27
(-10%)
3-Year Target
$1.20
(-14%)
3-Yr Target (if PE normalizes)
(PE: 58→68)
$1.40
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 58.3, Growth: -63.1%)
$1.02
(+-27%)
Base:
(SPY PE: 20.6, Growth: -63.1%)
$0.36
(-74%)
Bear:
(PE: 17.5, Growth: -63.1%)
$0.31
(-78%)
📈
Valuation based on Current Earnings
Trailing PE: 13.09 | Current EPS (TTM): $0.11
Bull Case
$0.79
(-43%)
Analyst growth -50.0%, PE expands to 14.4
Base Case
$0.72
(-49%)
Market implied -50.0%, PE stable at 13.1
Bear Case
$0.98
(-30%)
Severe decline -20.0%, PE contracts to 11.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 58.3 to 67.9
Stabilization Target:
$1.63
(+16.4%)
PE Expansion Potential:
+16.4%
Share & Embed Analysis
Last updated: April 29, 2026 5:54 AM ET
Data refreshes hourly during market hours. Next update: 6:54 AM
Data refreshes hourly during market hours. Next update: 6:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$186 | 60 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$150 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$94 | 58 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
